… require specificity of delivery to cancer cells, whilst sparing … including their incorporation
into therapeutic proteins. As the … to target specific protein–protein interactions integral to …

… used cancer therapeutics are effective inhibitors of vascular mimicry, developing a new
class of vascular mimicry … of the pro vascular mimicry protein MMP-2. cAMP inhibits vascular …

… Although numerous genes and proteins linked with VM have been reported previously,10
this review will focus on important phytochemicals that affect genes and proteins associated …

… interactions is thought to be a potential strategy for cancer therapeutics. … proteins leads to
more versatile applications in drug design and therapeutic approaches, including the mimicry …

… remarkable therapeutic effects in ovarian cancer patients. … are also used as ovarian cancer
therapeutics. Angiopoietin 1 … significantly correlated with VM and protein kinase Ca (PKCa…

… levels as a cancer-specific therapeutic vulnerability that can be elevated by viral mimicry–inducing …
Improved understanding of viral mimicry signaling and tolerance mechanisms reveals …

… breast cancer (TNBC) is the most aggressive breast cancer subtype with the worst prognosis
and few effective therapies. Here we identified MS023, an inhibitor of type I protein arginine …

… The discovery of vasculogenic mimicry (VM) provides a new therapeutic … PI3K proteins
are commonly found in a wide variety of cancers and have been … VM and cancer therapeutic …

… , we confirmed mimicry of tumor cell growth inhibition mediated by the recombinant VIT protein
only. In contrast, the vWA domain polypeptide did not significantly block cancer cell growth…

… mimicry of protein sites because such peptides can be generated as exact copies of protein
… laboratories in the use of synthetic protein mimics to modulate protein function, as well as to …